Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Identifieur interne : 002526 ( Ncbi/Curation ); précédent : 002525; suivant : 002527Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Auteurs : J. Vansteenkiste [Belgique] ; F. Barlesi [France] ; C F Waller [Allemagne] ; J. Bennouna [France] ; C. Gridelli [Italie] ; E. Goekkurt [Allemagne] ; D. Verhoeven [Belgique] ; A. Szczesna [Pologne] ; M. Feurer [Allemagne] ; J. Milanowski [Pologne] ; P. Germonpre [Belgique] ; H. Lena [France] ; D. Atanackovic [Allemagne] ; M. Krzakowski [Pologne] ; C. Hicking [Allemagne] ; J. Straub [Allemagne] ; M. Picard [Allemagne] ; W. Schuette [Allemagne] ; K. O'Byrne [Australie]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Adénocarcinome (anatomopathologie), Adénocarcinome (métabolisme), Adénocarcinome (traitement médicamenteux), Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (métabolisme), Carcinome pulmonaire non à petites cellules (traitement médicamenteux), Carcinome épidermoïde (anatomopathologie), Carcinome épidermoïde (métabolisme), Carcinome épidermoïde (traitement médicamenteux), Cisplatine (administration et posologie), Cétuximab (administration et posologie), Désoxycytidine (administration et posologie), Désoxycytidine (analogues et dérivés), Femelle, Humains, Intégrine alphaVbêta3 (métabolisme), Modèles de hasards proportionnels, Mâle, Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Récepteur du facteur de croissance épidermique (métabolisme), Récepteur vitronectine (métabolisme), Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (traitement médicamenteux), Venins de serpent (administration et posologie), Vinblastine (administration et posologie), Vinblastine (analogues et dérivés).
- MESH :
- administration et posologie : Cisplatine, Cétuximab, Désoxycytidine, Venins de serpent, Vinblastine.
- analogues et dérivés : Désoxycytidine, Vinblastine.
- anatomopathologie : Adénocarcinome, Carcinome pulmonaire non à petites cellules, Carcinome épidermoïde, Tumeurs du poumon.
- métabolisme : Adénocarcinome, Carcinome pulmonaire non à petites cellules, Carcinome épidermoïde, Intégrine alphaVbêta3, Récepteur du facteur de croissance épidermique, Récepteur vitronectine.
- traitement médicamenteux : Adénocarcinome, Carcinome pulmonaire non à petites cellules, Carcinome épidermoïde, Tumeurs du poumon.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Modèles de hasards proportionnels, Mâle, Pronostic, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute.
English descriptors
- KwdEn :
- Adenocarcinoma (drug therapy), Adenocarcinoma (metabolism), Adenocarcinoma (pathology), Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Carcinoma, Non-Small-Cell Lung (drug therapy), Carcinoma, Non-Small-Cell Lung (metabolism), Carcinoma, Non-Small-Cell Lung (pathology), Carcinoma, Squamous Cell (drug therapy), Carcinoma, Squamous Cell (metabolism), Carcinoma, Squamous Cell (pathology), Cetuximab (administration & dosage), Cisplatin (administration & dosage), Deoxycytidine (administration & dosage), Deoxycytidine (analogs & derivatives), Disease-Free Survival, Female, Humans, Integrin alphaVbeta3 (metabolism), Lung Neoplasms (drug therapy), Lung Neoplasms (pathology), Male, Middle Aged, Prognosis, Proportional Hazards Models, Receptor, Epidermal Growth Factor (metabolism), Receptors, Vitronectin (metabolism), Snake Venoms (administration & dosage), Treatment Outcome, Vinblastine (administration & dosage), Vinblastine (analogs & derivatives).
- MESH :
- chemical , administration & dosage : Cetuximab, Cisplatin, Deoxycytidine, Snake Venoms, Vinblastine.
- chemical , analogs & derivatives : Deoxycytidine, Vinblastine.
- drug therapy : Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms.
- metabolism : Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Integrin alphaVbeta3, Receptor, Epidermal Growth Factor, Receptors, Vitronectin.
- pathology : Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Male, Middle Aged, Prognosis, Proportional Hazards Models, Treatment Outcome.
Abstract
This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC).
DOI: 10.1093/annonc/mdv219
PubMed: 25939894
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A71
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002A01
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002A01
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002526
Links to Exploration step
pubmed:25939894Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).</title><author><name sortKey="Vansteenkiste, J" sort="Vansteenkiste, J" uniqKey="Vansteenkiste J" first="J" last="Vansteenkiste">J. Vansteenkiste</name><affiliation wicri:level="1"><nlm:affiliation>Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospitals KU Leuven, Leuven, Belgium johan.vansteenkiste@uzleuven.be.</nlm:affiliation><country wicri:rule="url">Belgique</country><wicri:regionArea>Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospitals KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Barlesi, F" sort="Barlesi, F" uniqKey="Barlesi F" first="F" last="Barlesi">F. Barlesi</name><affiliation wicri:level="3"><nlm:affiliation>Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University-Assistance Publique Hôpitaux de Marseille, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University-Assistance Publique Hôpitaux de Marseille, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Waller, C F" sort="Waller, C F" uniqKey="Waller C" first="C F" last="Waller">C F Waller</name><affiliation wicri:level="3"><nlm:affiliation>Haematology, Oncology and Stem Cell Transplantation, University Hospital of Freiburg, Freiburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Haematology, Oncology and Stem Cell Transplantation, University Hospital of Freiburg, Freiburg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Fribourg-en-Brisgau</region><settlement type="city">Fribourg-en-Brisgau</settlement></placeName></affiliation></author><author><name sortKey="Bennouna, J" sort="Bennouna, J" uniqKey="Bennouna J" first="J" last="Bennouna">J. Bennouna</name><affiliation wicri:level="1"><nlm:affiliation>Département d'Oncologie Médicale, Centre Rene Gauducheau, Saint-Herblain Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Oncologie Médicale, Centre Rene Gauducheau, Saint-Herblain Cedex</wicri:regionArea><wicri:noRegion>Saint-Herblain Cedex</wicri:noRegion><wicri:noRegion>Saint-Herblain Cedex</wicri:noRegion></affiliation></author><author><name sortKey="Gridelli, C" sort="Gridelli, C" uniqKey="Gridelli C" first="C" last="Gridelli">C. Gridelli</name><affiliation wicri:level="1"><nlm:affiliation>Division of Medical Oncology, Azienda Ospedaliera 'S.G. Moscati', Avellino, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Medical Oncology, Azienda Ospedaliera 'S.G. Moscati', Avellino</wicri:regionArea><wicri:noRegion>Avellino</wicri:noRegion></affiliation></author><author><name sortKey="Goekkurt, E" sort="Goekkurt, E" uniqKey="Goekkurt E" first="E" last="Goekkurt">E. Goekkurt</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Hematology, Stem Cell Transplantation and Hemostaseology, University Hospital Aachen, Aachen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Oncology, Hematology, Stem Cell Transplantation and Hemostaseology, University Hospital Aachen, Aachen</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Aix-la-Chapelle</settlement></placeName></affiliation></author><author><name sortKey="Verhoeven, D" sort="Verhoeven, D" uniqKey="Verhoeven D" first="D" last="Verhoeven">D. Verhoeven</name><affiliation wicri:level="1"><nlm:affiliation>Iridium Cancer Network, Medical Oncology, AZ Klina, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Iridium Cancer Network, Medical Oncology, AZ Klina, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Szczesna, A" sort="Szczesna, A" uniqKey="Szczesna A" first="A" last="Szczesna">A. Szczesna</name><affiliation wicri:level="1"><nlm:affiliation>Mazowieckie Centrum Leczenia Chorób Pluc i Gruźlicy, Otwock, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Mazowieckie Centrum Leczenia Chorób Pluc i Gruźlicy, Otwock</wicri:regionArea><wicri:noRegion>Otwock</wicri:noRegion></affiliation></author><author><name sortKey="Feurer, M" sort="Feurer, M" uniqKey="Feurer M" first="M" last="Feurer">M. Feurer</name><affiliation wicri:level="3"><nlm:affiliation>Lungenpraxis Munich, Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Lungenpraxis Munich, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Milanowski, J" sort="Milanowski, J" uniqKey="Milanowski J" first="J" last="Milanowski">J. Milanowski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin</wicri:regionArea><wicri:noRegion>Lublin</wicri:noRegion></affiliation></author><author><name sortKey="Germonpre, P" sort="Germonpre, P" uniqKey="Germonpre P" first="P" last="Germonpre">P. Germonpre</name><affiliation wicri:level="1"><nlm:affiliation>Pulmonary Medicine, AZ Maria Middelares, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Pulmonary Medicine, AZ Maria Middelares, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Lena, H" sort="Lena, H" uniqKey="Lena H" first="H" last="Lena">H. Lena</name><affiliation wicri:level="3"><nlm:affiliation>Pneumology, CHU Rennes, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pneumology, CHU Rennes, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Atanackovic, D" sort="Atanackovic, D" uniqKey="Atanackovic D" first="D" last="Atanackovic">D. Atanackovic</name><affiliation wicri:level="3"><nlm:affiliation>Oncology/Hematology/Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Oncology/Hematology/Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg</wicri:regionArea><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Krzakowski, M" sort="Krzakowski, M" uniqKey="Krzakowski M" first="M" last="Krzakowski">M. Krzakowski</name><affiliation wicri:level="1"><nlm:affiliation>The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Lung and Thoracic Tumours, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Lung and Thoracic Tumours, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Hicking, C" sort="Hicking, C" uniqKey="Hicking C" first="C" last="Hicking">C. Hicking</name><affiliation wicri:level="3"><nlm:affiliation>Merck KGaA, Darmstadt.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Darmstadt</settlement><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region></placeName><wicri:orgArea>Merck KGaA</wicri:orgArea></affiliation></author><author><name sortKey="Straub, J" sort="Straub, J" uniqKey="Straub J" first="J" last="Straub">J. Straub</name><affiliation wicri:level="3"><nlm:affiliation>Merck KGaA, Darmstadt.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Darmstadt</settlement><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region></placeName><wicri:orgArea>Merck KGaA</wicri:orgArea></affiliation></author><author><name sortKey="Picard, M" sort="Picard, M" uniqKey="Picard M" first="M" last="Picard">M. Picard</name><affiliation wicri:level="3"><nlm:affiliation>Merck KGaA, Darmstadt.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Darmstadt</settlement><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region></placeName><wicri:orgArea>Merck KGaA</wicri:orgArea></affiliation></author><author><name sortKey="Schuette, W" sort="Schuette, W" uniqKey="Schuette W" first="W" last="Schuette">W. Schuette</name><affiliation wicri:level="1"><nlm:affiliation>Krankenhaus Martha-Maria Halle-Dölau, Klinik für Innere Medizin II, Halle, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Krankenhaus Martha-Maria Halle-Dölau, Klinik für Innere Medizin II, Halle</wicri:regionArea><wicri:noRegion>Halle</wicri:noRegion><wicri:noRegion>Halle</wicri:noRegion><wicri:noRegion>Halle</wicri:noRegion></affiliation></author><author><name sortKey="O Byrne, K" sort="O Byrne, K" uniqKey="O Byrne K" first="K" last="O'Byrne">K. O'Byrne</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Services, Princess Alexandra Hospital, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25939894</idno><idno type="pmid">25939894</idno><idno type="doi">10.1093/annonc/mdv219</idno><idno type="wicri:Area/PubMed/Corpus">002A71</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A71</idno><idno type="wicri:Area/PubMed/Curation">002A01</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A01</idno><idno type="wicri:Area/PubMed/Checkpoint">002A01</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A01</idno><idno type="wicri:Area/Ncbi/Merge">002526</idno><idno type="wicri:Area/Ncbi/Curation">002526</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).</title><author><name sortKey="Vansteenkiste, J" sort="Vansteenkiste, J" uniqKey="Vansteenkiste J" first="J" last="Vansteenkiste">J. Vansteenkiste</name><affiliation wicri:level="1"><nlm:affiliation>Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospitals KU Leuven, Leuven, Belgium johan.vansteenkiste@uzleuven.be.</nlm:affiliation><country wicri:rule="url">Belgique</country><wicri:regionArea>Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospitals KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Barlesi, F" sort="Barlesi, F" uniqKey="Barlesi F" first="F" last="Barlesi">F. Barlesi</name><affiliation wicri:level="3"><nlm:affiliation>Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University-Assistance Publique Hôpitaux de Marseille, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University-Assistance Publique Hôpitaux de Marseille, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Waller, C F" sort="Waller, C F" uniqKey="Waller C" first="C F" last="Waller">C F Waller</name><affiliation wicri:level="3"><nlm:affiliation>Haematology, Oncology and Stem Cell Transplantation, University Hospital of Freiburg, Freiburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Haematology, Oncology and Stem Cell Transplantation, University Hospital of Freiburg, Freiburg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Fribourg-en-Brisgau</region><settlement type="city">Fribourg-en-Brisgau</settlement></placeName></affiliation></author><author><name sortKey="Bennouna, J" sort="Bennouna, J" uniqKey="Bennouna J" first="J" last="Bennouna">J. Bennouna</name><affiliation wicri:level="1"><nlm:affiliation>Département d'Oncologie Médicale, Centre Rene Gauducheau, Saint-Herblain Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Oncologie Médicale, Centre Rene Gauducheau, Saint-Herblain Cedex</wicri:regionArea><wicri:noRegion>Saint-Herblain Cedex</wicri:noRegion><wicri:noRegion>Saint-Herblain Cedex</wicri:noRegion></affiliation></author><author><name sortKey="Gridelli, C" sort="Gridelli, C" uniqKey="Gridelli C" first="C" last="Gridelli">C. Gridelli</name><affiliation wicri:level="1"><nlm:affiliation>Division of Medical Oncology, Azienda Ospedaliera 'S.G. Moscati', Avellino, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Medical Oncology, Azienda Ospedaliera 'S.G. Moscati', Avellino</wicri:regionArea><wicri:noRegion>Avellino</wicri:noRegion></affiliation></author><author><name sortKey="Goekkurt, E" sort="Goekkurt, E" uniqKey="Goekkurt E" first="E" last="Goekkurt">E. Goekkurt</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Hematology, Stem Cell Transplantation and Hemostaseology, University Hospital Aachen, Aachen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Oncology, Hematology, Stem Cell Transplantation and Hemostaseology, University Hospital Aachen, Aachen</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Aix-la-Chapelle</settlement></placeName></affiliation></author><author><name sortKey="Verhoeven, D" sort="Verhoeven, D" uniqKey="Verhoeven D" first="D" last="Verhoeven">D. Verhoeven</name><affiliation wicri:level="1"><nlm:affiliation>Iridium Cancer Network, Medical Oncology, AZ Klina, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Iridium Cancer Network, Medical Oncology, AZ Klina, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Szczesna, A" sort="Szczesna, A" uniqKey="Szczesna A" first="A" last="Szczesna">A. Szczesna</name><affiliation wicri:level="1"><nlm:affiliation>Mazowieckie Centrum Leczenia Chorób Pluc i Gruźlicy, Otwock, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Mazowieckie Centrum Leczenia Chorób Pluc i Gruźlicy, Otwock</wicri:regionArea><wicri:noRegion>Otwock</wicri:noRegion></affiliation></author><author><name sortKey="Feurer, M" sort="Feurer, M" uniqKey="Feurer M" first="M" last="Feurer">M. Feurer</name><affiliation wicri:level="3"><nlm:affiliation>Lungenpraxis Munich, Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Lungenpraxis Munich, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Milanowski, J" sort="Milanowski, J" uniqKey="Milanowski J" first="J" last="Milanowski">J. Milanowski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Lublin</wicri:regionArea><wicri:noRegion>Lublin</wicri:noRegion></affiliation></author><author><name sortKey="Germonpre, P" sort="Germonpre, P" uniqKey="Germonpre P" first="P" last="Germonpre">P. Germonpre</name><affiliation wicri:level="1"><nlm:affiliation>Pulmonary Medicine, AZ Maria Middelares, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Pulmonary Medicine, AZ Maria Middelares, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Lena, H" sort="Lena, H" uniqKey="Lena H" first="H" last="Lena">H. Lena</name><affiliation wicri:level="3"><nlm:affiliation>Pneumology, CHU Rennes, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pneumology, CHU Rennes, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Atanackovic, D" sort="Atanackovic, D" uniqKey="Atanackovic D" first="D" last="Atanackovic">D. Atanackovic</name><affiliation wicri:level="3"><nlm:affiliation>Oncology/Hematology/Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Oncology/Hematology/Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg</wicri:regionArea><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Krzakowski, M" sort="Krzakowski, M" uniqKey="Krzakowski M" first="M" last="Krzakowski">M. Krzakowski</name><affiliation wicri:level="1"><nlm:affiliation>The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Lung and Thoracic Tumours, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Lung and Thoracic Tumours, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Hicking, C" sort="Hicking, C" uniqKey="Hicking C" first="C" last="Hicking">C. Hicking</name><affiliation wicri:level="3"><nlm:affiliation>Merck KGaA, Darmstadt.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Darmstadt</settlement><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region></placeName><wicri:orgArea>Merck KGaA</wicri:orgArea></affiliation></author><author><name sortKey="Straub, J" sort="Straub, J" uniqKey="Straub J" first="J" last="Straub">J. Straub</name><affiliation wicri:level="3"><nlm:affiliation>Merck KGaA, Darmstadt.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Darmstadt</settlement><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region></placeName><wicri:orgArea>Merck KGaA</wicri:orgArea></affiliation></author><author><name sortKey="Picard, M" sort="Picard, M" uniqKey="Picard M" first="M" last="Picard">M. Picard</name><affiliation wicri:level="3"><nlm:affiliation>Merck KGaA, Darmstadt.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Darmstadt</settlement><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region></placeName><wicri:orgArea>Merck KGaA</wicri:orgArea></affiliation></author><author><name sortKey="Schuette, W" sort="Schuette, W" uniqKey="Schuette W" first="W" last="Schuette">W. Schuette</name><affiliation wicri:level="1"><nlm:affiliation>Krankenhaus Martha-Maria Halle-Dölau, Klinik für Innere Medizin II, Halle, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Krankenhaus Martha-Maria Halle-Dölau, Klinik für Innere Medizin II, Halle</wicri:regionArea><wicri:noRegion>Halle</wicri:noRegion><wicri:noRegion>Halle</wicri:noRegion><wicri:noRegion>Halle</wicri:noRegion></affiliation></author><author><name sortKey="O Byrne, K" sort="O Byrne, K" uniqKey="O Byrne K" first="K" last="O'Byrne">K. O'Byrne</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Services, Princess Alexandra Hospital, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (drug therapy)</term><term>Adenocarcinoma (metabolism)</term><term>Adenocarcinoma (pathology)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term><term>Carcinoma, Non-Small-Cell Lung (metabolism)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Carcinoma, Squamous Cell (drug therapy)</term><term>Carcinoma, Squamous Cell (metabolism)</term><term>Carcinoma, Squamous Cell (pathology)</term><term>Cetuximab (administration & dosage)</term><term>Cisplatin (administration & dosage)</term><term>Deoxycytidine (administration & dosage)</term><term>Deoxycytidine (analogs & derivatives)</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Integrin alphaVbeta3 (metabolism)</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (pathology)</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Proportional Hazards Models</term><term>Receptor, Epidermal Growth Factor (metabolism)</term><term>Receptors, Vitronectin (metabolism)</term><term>Snake Venoms (administration & dosage)</term><term>Treatment Outcome</term><term>Vinblastine (administration & dosage)</term><term>Vinblastine (analogs & derivatives)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Adénocarcinome (anatomopathologie)</term><term>Adénocarcinome (métabolisme)</term><term>Adénocarcinome (traitement médicamenteux)</term><term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term><term>Carcinome pulmonaire non à petites cellules (métabolisme)</term><term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term><term>Carcinome épidermoïde (anatomopathologie)</term><term>Carcinome épidermoïde (métabolisme)</term><term>Carcinome épidermoïde (traitement médicamenteux)</term><term>Cisplatine (administration et posologie)</term><term>Cétuximab (administration et posologie)</term><term>Désoxycytidine (administration et posologie)</term><term>Désoxycytidine (analogues et dérivés)</term><term>Femelle</term><term>Humains</term><term>Intégrine alphaVbêta3 (métabolisme)</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Récepteur du facteur de croissance épidermique (métabolisme)</term><term>Récepteur vitronectine (métabolisme)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (traitement médicamenteux)</term><term>Venins de serpent (administration et posologie)</term><term>Vinblastine (administration et posologie)</term><term>Vinblastine (analogues et dérivés)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cetuximab</term><term>Cisplatin</term><term>Deoxycytidine</term><term>Snake Venoms</term><term>Vinblastine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Deoxycytidine</term><term>Vinblastine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Cisplatine</term><term>Cétuximab</term><term>Désoxycytidine</term><term>Venins de serpent</term><term>Vinblastine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Désoxycytidine</term><term>Vinblastine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome</term><term>Carcinome pulmonaire non à petites cellules</term><term>Carcinome épidermoïde</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term><term>Carcinoma, Non-Small-Cell Lung</term><term>Carcinoma, Squamous Cell</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Adenocarcinoma</term><term>Carcinoma, Non-Small-Cell Lung</term><term>Carcinoma, Squamous Cell</term><term>Integrin alphaVbeta3</term><term>Receptor, Epidermal Growth Factor</term><term>Receptors, Vitronectin</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Adénocarcinome</term><term>Carcinome pulmonaire non à petites cellules</term><term>Carcinome épidermoïde</term><term>Intégrine alphaVbêta3</term><term>Récepteur du facteur de croissance épidermique</term><term>Récepteur vitronectine</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term><term>Carcinoma, Non-Small-Cell Lung</term><term>Carcinoma, Squamous Cell</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome</term><term>Carcinome pulmonaire non à petites cellules</term><term>Carcinome épidermoïde</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Proportional Hazards Models</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Pronostic</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC).</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002526 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002526 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:25939894
|texte= Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:25939894" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |